Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers

NCT03073473 is registered in ClinicalTrials.gov with Cota Inc. as lead sponsor.

NCT NCT03073473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03073473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Lead sponsor
Cota Inc.
Phase
Observational
Overall status
Terminated
Start date
February 28, 2017
Completion date
June 13, 2018
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, metastatic colon cancer, metastatic lung cancer, metastatic melanoma, metastatic prostate cancer, pancreatic cancer